Dr. Ronald Perrone Joins XORTX Clinical Advisory Board

Ronald Perrone, MD, has joined the clinical advisory board of XORTX Therapeutics, Inc. The biopharmaceutical company focuses on developing therapies to treat autosomal dominant polycystic kidney disease (ADPKD).

Dr. Perrone is board-certified in nephrology and serves as professor of medicine at Tufts University School of Medicine in Boston, Massachusetts. His clinical research focuses on kidney disease with an emphasis on polycystic kidney disease (PKD). He has collaborated with regulatory agencies such as the US Food and Drug Administration (FDA) to help develop database assessment tools to validate total kidney volume as a biomarker for PKD progression.

In addition, Dr. Perrone has participated in many ADPKD trials and initiated a PKD database consortium in 2007, which led to the creation of the PKD Outcomes Consortium. The PKD Outcomes Consortium, which includes contributors from academia, the pharmaceutical industry, the National Institutes of Health, the FDA, the Clinical Data Interchange Standards Consortium, and the Critical Path Institute, is laying the foundation for the validation of biomarkers as well as clinical trial and regulatory endpoints in ADPKD.

“We are excited that Dr. Ron Perrone has agreed to join XORTX’s Clinical Advisory Board. Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease,” said Allen Davidoff, PhD, founder and chief executive officer of XORTX. “We look forward to the valuable contributions that he can bring to our advanced clinical program and specifically the XRX-OXY-201 registration trial designed to slow progression of ADPKD.”